The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C and Body Piercing

Back to News Homepage

Next

BiolineRX Gains Momentum for Pre-Clinical HCV Drug

New Strategy Shifts Pfizer Away from New Hep C Drug

March 15, 2013

Print this page

By discontinuing development on filibuvir, Pfizer takes a back seat in the race for an improved Hepatitis C drug regimen.

Pfizer Stops Developing Hepatitis C Drug, Cites Strategic Review

Published March 08, 2013 | Dow Jones Newswires

Pfizer Inc. (PFE) has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.

The New York-based drug giant decided to discontinue development of PF-00868554, also known as filibuvir, following a strategic review, said spokeswoman Victoria Davis. She said the decision wasn’t related to any safety issues.

Continue reading this entire article:
http://www.foxbusiness.com/news/2013/03/08/pfizer-stops-developing-hepatitis-c-drug-cites-strategic-review/

No Comments - be the first!
Share
Share

Previous

Hepatitis C and Body Piercing

Back to News Homepage

Next

BiolineRX Gains Momentum for Pre-Clinical HCV Drug

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.